By Michael Gottesman
Thursday, June 7, 2018
Like many research institutions across the nation, the NIH has faced difficulties with establishing a strong and lasting community of diverse investigators. We have made remarkable gains in recent years, however, in attracting and retaining a diverse workforce that's more reflective of the U.S. population.
One of many movers and shakers in this realm is Hannah Valantine, a cardiologist recruited from Stanford University who, in addition to maintaining a lab in NHLBI, is the NIH's first Chief Officer for Scientific Workforce Diversity. And one of her many ideas that the NIH Scientific Directors hope to adopt is the creation of a cohort program with both mentors and mentees committed to issues of scientific diversity and inclusion. Our goal is to guide this cohort of tenure-track investigators through the tenure process to be sure they have access to the mentoring, professional development, and networking opportunities to establish their careers, strengthen their science, and, in turn, recruit and mentor future generations of scientists.
By Michael Gottesman
Monday, June 4, 2018
The NIH Lasker Clinical Research Scholar Program, an initiative to support early-stage clinical researchers, has reached a milestone. First announced in December 2010, the program provides scholars with up to ten years of support: five to seven years as NIH tenure-track investigators, followed by three years additional funding at an extramural research institution, pending review, if they choose to leave the NIH. Our goal was to recruit a few scholars each year and have a “steady state” of 15 to 20 scholars on campus. We indeed are now up to 15 scholars, which meets this goal.
By Michael Gottesman
Thursday, May 31, 2018
A fascinating statistic crossed my desk this month: Among U.S.-based institutions, the NIH has the highest representation of women scientists and engineers on filed international patent applications. I can believe it, and there’s a report documenting it from the World Intellectual Property Office (WIPO), a UN-affiliated organization.
By Michael Gottesman
Thursday, May 24, 2018
Theodor Kolobow, M.D., passed away on March 24, 2018. He was 87 years old. His contributions while at the NHLBI to the field of cardiovascular and pulmonary research fall nothing short of extraordinary, and include advancements in the development of artificial organs, and the pathophysiology of acute lung injury. Over the course of his career he was actively involved in the innovation and development of new dialysis machines, cuffless endotracheal tubes, and devices to prop open right-sided heart valves, thereby preventing left heart distention during percutaneous cardiopulmonary bypass. He designed special low-resistance endotracheal tubes to limit the necessary ventilatory pressure, in addition to endotracheal tubes that would help to limit bacterial colonization and methods for preventing ventilator associated pneumonias.
By Michael Gottesman
Tuesday, May 22, 2018
NIH history is rife with legends, scientists who have made remarkable discoveries and incalculable contributions to the health and longevity of humankind. There are living legends; just peruse the “Honors” page on the IRP website to see what I mean. And there are greats who are gone but certainly not forgotten.
By Michael Gottesman
Monday, May 21, 2018
James F. Holland, M.D., a renowned cancer expert who was a major figure in the development of cancer chemotherapy, died on March 22, 2018, at the age of 92. Dr. Holland was among the first group of research physicians recruited to the NIH Clinical Center, serving as a senior surgeon at the National Cancer Institute from 1953 to 1954. In that short year at the NIH, he initiated a clinical trial to compare continuous or intermittent treatment with two chemotherapy agents for acute leukemia in children: methotrexate and 6-mercaptopurine. Dr. Holland moved to Roswell Park Memorial Institute in Buffalo before the trial was completed, but he continued to collaborate. His work ultimately turned an incurable illness into one with an 80% survival rate. In 1972, he and his NIH collaborators shared the Albert Lasker Clinical Medical Research Award for "outstanding contribution to the concept and application of combination therapy in the treatment of acute leukemia in children."
By Michael Gottesman
Tuesday, January 9, 2018
We’ve had a few changes on our Board of Scientific Directors in the past year, so I thought I’d give you an update. Each NIH Institute or Center (IC) with an intramural program has a scientific director (SD). The NCI, NIAID, NLM, and NIEHS are programmatically diverse and require additional leaders with SD functions. So, although 24 ICs have principal SDs, there are actually 30 people who function as scientific directors.
These SDs are responsible for the intramural budgets of their institutes. Most run their own labs. They also have numerous other responsibilities, which include:
By Michael Gottesman
Tuesday, October 24, 2017
There are many ways to categorize the research performed at the NIH Intramural Research Program: biomedical or behavioral; computational, basic, translational, or clinical; excellent or outstanding; wow or double-wow; and so on. When we launched the irp.nih.gov website, we utilized the concept of scientific focus areas, or SFAs, and identified 21 such SFAs at the IRP, from biomedical engineering & biophysics to virology.
We thought the 21 SFAs did a rather nice job of summing up all the diverse science in the IRP. Then along comes RNA biology. It's not as if the field is new; some 30 Nobel Prizes have been won involving RNA over the decades. But the field has had a renaissance in recent years with discoveries such as that of noncoding RNA (ncRNA) functioning in genome defense and chromosome inactivation. Newly revealed classes of RNAs and their remarkable functions are poised to revolutionize molecular biology, with profound implications for clinical sciences.
By Michael Gottesman
Thursday, June 22, 2017
Michael A. Beaven died unexpectedly on Saturday, April 8, 2017, at age 80. Mike was an expert in mast cell biology and beloved friend and colleague of many. He had worked at the NIH since 1962.
In the past seven years during his formal “retirement,” Mike remained incredibly productive, coauthoring more than 20 primary publications as well as a number of reviews; and he continued to perform experimental work as well as being the “go to” scholar in a range of areas.
By Michael Gottesman
Tuesday, May 9, 2017
The NIH Lasker Clinical Research Scholars Program is approaching a milestone. This program is a unique intramural–extramural partnership that aims to nurture a new generation of clinical researchers with dedicated support to help them establish a research career.
